As mentioned in the literature review, the conclusion on grade 3 or greater AEs for EGFR-TKIs against chemotherapy in EGFR mutation-positive NSCLC patients is inconsistent.[6,16] These results provide further support for the hypothesis that NSCLC patents with the T790M mutation receiving Osimertinib could have fewer grade 3 or greater AEs than those receiving EGFR-TKIs/chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.